Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664486 | 0.81 | GNRHR (0.41) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5663527 | 0.80 | GNRHR (0.46) | — | |
| SCHEMBL8985017 | 0.69 | ATM (0.61) | ATMCTSSCTSKCTSBCTSL | |
| SCHEMBL18569400 | 0.68 | PPARA (0.60) | ATMCTSSCTSKCTSBCTSL | |
| SCHEMBL16459752 | 0.68 | CTSS (0.68) | ATMCTSSCTSKCTSBCTSL | |
| Dimethylamine SCHEMBL1435916 | 0.68 | ATM (0.60) | ATMCTSSCTSKCTSBCTSL | |
| SCHEMBL18435382 | 0.68 | CTSS (0.68) | ATMCTSSCTSKCTSBCTSL | |
| SCHEMBL16459753 | 0.68 | CTSS (0.68) | ATMCTSSCTSKCTSBCTSL | |
| SCHEMBL12203694 | 0.68 | NPC1 (0.63) | ATMCTSSCTSKCTSBCTSL | |
| SCHEMBL7939304 | 0.68 | ATM (0.63) | ATMCTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081459-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20050272733-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| US-6921761-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040266773-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6750350-B2 | THERAPY FOR SEXUAL DISORDERS | NEUROCRINE BIOSCIENCES, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030073693-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266773-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | ATM 4794/4885CTSS 1549/4885CTSK 2092/4885 |
| US-20050272733-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | ATM 4636/4885CTSS 1817/4885CTSK 2600/4885 |
| US-20030073693-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | ATM 4794/4885CTSS 1549/4885CTSK 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.